Skip to content

Study · Animal study (in vivo) · rat · 2020

1 result

Brain and kidney GHS-R1a underexpression is associated with changes in renal function and hemodynamics during neurogenic hypertension.

Sales da Silva E, Ferreira PM, Castro CH, Pacheco LF, Graziani D, Pontes CNR, Bessa ASM, Fernandes E, Naves LM, Ribeiro LCDS, Mendonça MM, Gomes RM, Pedrino GR, Ferreira RN, Xavier CH

Molecular and cellular endocrinology16 Aug 2020Cited by 6 (Europe PMC)

PMID32814069 (opens in a new tab)DOI10.1016/j.mce.2020.110984 (opens in a new tab)PepBankPUB-32814069
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In spontaneously hypertensive rats, MK‑677 changed osmolarity parameters in a GHS-R1a-dependent manner.

    In plain wordsIn rats with hypertension, MK‑677 changed osmolarity parameters through GHS-R1a.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    Direction not reportedOsmolarity parameters
    Study

    ratn: not reported in source

    Spontaneously hypertensive rats
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We found that ghrelin and MK-677 changed osmolarity parameters of SHR, in a GHS-R1a-dependent manner.
    2 context sentences
    Summary · context
    To investigate GHS-R1a role on renal function and hemodynamics, we used Wistar (WT) and spontaneously hypertensive rats (SHR).
    Summary · context
    First, we assessed the effect of systemically injected vehicle, ghrelin, GHS-R1a antagonist PF04628935, ghrelin plus PF04628935 or GHS-R1a synthetic agonist MK-677 in WT and SHR rats housed in metabolic cages (24 h).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.